2022-台灣高血脂初級預防指引- 7. LDL目標值-中度風險民眾

2025-12-09 11:08AM
2022台灣血脂治療指引(英文版)下面中文使用google自動翻譯

中度風險（≥2個風險因子）：根據專家共識，對於具有2個風險因子的受試者，啟動治療和治療目標的LDL-C水準為115 mg/dL。此建議的LDL-C水平與2019年ESC血脂指引中建議的低風險族群LDL-C目標值<116 mg/dL相近。 ¹⁸ 建議的LDL-C目標值115 mg/dL低於日本和韓國血脂指引中的數值，日本指引中中度風險族群的LDL-C目標值為<140 mg/dL，韓國指引中具有2個或以上主要風險因子族群的LDL-C目標值為<130 mg/dL。 ^39,40 如果在生活方式調整3個月後，LDL-C水平仍高於目標值，則首先考慮使用中等強度的他汀類藥物。

建議：對於具有 2 項危險因子且 LDL-C ≥ 115 mg/dL 的受試者，應開始非藥物治療，LDL-C 目標值為 < 115 mg/dL。 （證據等級 IIa，證據等級 C）如果非藥物治療 3 個月後仍未達到治療目標，則應考慮中等強度他汀類藥物治療。 （證據等級 IIa，證據等級 C）

Moderate risk (‡2 risk factors) The LDL-C level for initiation of therapy and treatment target in subjects with
2 risk factors is 115 mg/dL based on the experts’ consensus. This recommended LDL-C level is close to the 2019 ESC lipid guidelines suggesting the LDLC target <116 mg/dL in the low risk individuals.18 The recommended LDL-C target of 115 mg/dL is lower than that in the Japanese and Korean lipid guidelines where the LDLC target is <140 mg/dL for moderate risk in Japan and <130 mg/dL for those with 2 or more major risk factors in Korea.39,40 Moderate-intensity statins are considered first if LDL-C remains higher than the target after 3 months of lifestyle adjustment.

Recommendation In subjects with
2 risk factors and LDL-C
115 mg/ dL, non-pharmacological therapy should be initiated and the LDL-C target is <115 mg/dL. (COR IIa, LOE C) If the treatment target is not met after 3 months of non-pharmacological therapy, moderate-intensity statin therapy should be considered (COR IIa, LOE C)